Please assess the completion status of the following clinical trial:

Trial Title: Capecitabine as Radiosensitising Agent in Neoadjuvant Treatment of Locally Advanced Resectable Rectal Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* histologically verified adenocarcinoma of the rectum,~* resectable clinical stage II or III (IUCC TNM classification 2002);~* no prior radiotherapy and/or chemotherapy;~* World Health Organisation (WHO) performance status \< 2;~* age at diagnosis of 18 or older;~* and adequate bone marrow, liver, renal and cardiac function (no history of ischemic heart disease).~Exclusion Criteria:~* A history of prior malignancy other than non-melanoma skin cancer or in situ carcinoma of the cervix

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).